纳维雅®(注射用三氧化二砷)在肝癌治疗新进展黑龙江嘉通药业黑龙江嘉通药业中国是肝癌发病重灾区GLOBOCAN2008(IARC),SectionofCancerInformation(19/10/2010)http://globocan
fr/factsheets/cancers/liver
aspGLOBOCAN2008(IARC),SectionofCancerInformation(19/10/2010)http://globocan
fr/factsheets/cancers/liver
6117Age-standardisedincidenceratesper100,000男性发病率:34
7/100,000(292,966例)女性发病率:13
7/100,000(109,242例)男性死亡率:34
1/100,000(226,830例)女性死亡率:13
1/100,000(105,249例)占全球病人的55%占全球病人的55%03
6117Age-standardisedincidenceratesper100,000OrganisationCountryYearEvidencebase中国卫生部中国2011Allstudytypes†——肝癌诊疗规范(2011版)1J-HCCJapan2010Allstudytypes†11APASL亚太地区2010Allstudytypes*2NCCNUS2009Mainlylevel2Aevidence(phaseII,cohort/casestudies&experience)3HUGUK2009Allstudytypes*4SpanishconsensusSpain2009Allstudytypes*5AustrianconsensusAustri